ResMed Inc. (NYSE:RMD - Free Report) - Stock analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for ResMed in a research report issued on Thursday, March 13th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $9.37 per share for the year, up from their previous forecast of $9.36. The consensus estimate for ResMed's current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed's Q4 2025 earnings at $2.41 EPS, Q1 2026 earnings at $2.31 EPS, Q2 2026 earnings at $2.41 EPS, FY2026 earnings at $9.71 EPS and Q1 2027 earnings at $2.51 EPS.
ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%.
RMD has been the subject of a number of other reports. Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. Stifel Nicolaus reduced their target price on shares of ResMed from $250.00 to $240.00 and set a "hold" rating on the stock in a report on Wednesday, March 5th. Piper Sandler lifted their price target on shares of ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a report on Friday, January 31st. Needham & Company LLC reissued a "hold" rating on shares of ResMed in a research note on Friday, January 31st. Finally, Morgan Stanley began coverage on ResMed in a research report on Wednesday. They set an "overweight" rating and a $280.00 target price for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, ResMed presently has an average rating of "Moderate Buy" and an average price target of $246.83.
Read Our Latest Stock Analysis on ResMed
ResMed Price Performance
Shares of RMD traded down $0.53 during mid-day trading on Monday, reaching $221.52. The company had a trading volume of 374,803 shares, compared to its average volume of 960,347. The company has a market capitalization of $32.53 billion, a price-to-earnings ratio of 26.08, a P/E/G ratio of 1.53 and a beta of 0.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The company's 50 day simple moving average is $235.48 and its 200 day simple moving average is $239.36. ResMed has a 1-year low of $172.19 and a 1-year high of $263.05.
ResMed Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be issued a dividend of $0.53 per share. The ex-dividend date is Thursday, February 13th. This represents a $2.12 annualized dividend and a yield of 0.96%. ResMed's payout ratio is 25.03%.
Insider Activity
In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the completion of the sale, the chief executive officer now directly owns 455,472 shares of the company's stock, valued at approximately $107,842,105.44. The trade was a 1.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the sale, the director now owns 77,218 shares of the company's stock, valued at $18,695,249.98. This trade represents a 2.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,940 shares of company stock worth $9,164,385 over the last three months. 0.71% of the stock is currently owned by insiders.
Institutional Investors Weigh In On ResMed
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of ResMed by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider's stock worth $4,156,089,000 after purchasing an additional 160,590 shares during the period. State Street Corp lifted its stake in ResMed by 1.9% in the third quarter. State Street Corp now owns 6,261,633 shares of the medical equipment provider's stock valued at $1,528,590,000 after purchasing an additional 116,918 shares during the last quarter. Geode Capital Management LLC grew its holdings in ResMed by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider's stock valued at $899,860,000 after purchasing an additional 85,270 shares during the period. Invesco Ltd. increased its position in ResMed by 32.2% in the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock worth $531,706,000 after buying an additional 566,046 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of ResMed by 20.6% during the 4th quarter. Northern Trust Corp now owns 1,702,590 shares of the medical equipment provider's stock valued at $389,365,000 after buying an additional 290,664 shares during the last quarter. Hedge funds and other institutional investors own 54.98% of the company's stock.
About ResMed
(
Get Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Further Reading
Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
